Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

ASX lithium stocks have surged as investors race to pick the bottom, following a lift in bargain basement lithium prices.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

In the DESTINY-Breast05 trial (NCT04622319), the antibody–drug conjugate trastuzumab deruxtecan, which has shown superiority to T-DM1 in second-line HER2-positive metastatic breast cancer 14 and ...

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...

Sara Hurvitz, MD, FACP, shares insights into the results of the HER2CLIMB-02 trial, which saw patients with HER2-positive breast cancer benefit from the addition of tucatinib to trastuzumab ...

Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

In the interim analysis, median PFS was not reached with T-DXd versus 6.8 months with T-DM1, and the risk of death or progression was reduced by 72% with T-DXd.

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast ...

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast ...

T-DMI induced clinically meaningful antitumor activity among patients with HER2-positive metastatic breast cancer and brain metastases, according to an exploratory analysis of the KAMILLA trial ...